Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 6INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 58Small Cell Lung Carcinoma 22Carcinoma, Hepatocellular 17Neoplasms 15Lung Neoplasms 14Biliary Tract Neoplasms 12Neoplasm Metastasis 11Breast Neoplasms 11Recurrence 10Squamous Cell Carcinoma of Head and Neck 9Melanoma 9Carcinoma 9Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Liver Neoplasms 7Head and Neck Neoplasms 7Urinary Bladder Neoplasms 6Ovarian Neoplasms 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Lymphoma 5Uterine Cervical Neoplasms 4Neoplasms by Site 4Multiple Myeloma 4Lymphoma, Follicular 4Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3

Interventions

Gemcitabine 12Cisplatin 10pembrolizumab 7Fluorouracil 7Leucovorin 6Oxaliplatin 5durvalumab 3Capecitabine 3zanidatamab 2Paclitaxel 2Irinotecan 2Folfox protocol 2Bevacizumab 2vandetanib 1tucatinib 1trastuzumab deruxtecan 1seribantumab 1merestinib 1lenvatinib 1irinotecan sucrosofate 1galactomannan 1fludarabine 1exatecan 1bintrafusp alfa protein, human 1becatecarin 1aldesleukin 1Trastuzumab 1Temozolomide 1Tegafur 1S 1 (combination) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Gallbladder Neoplasms × durvalumab × Clear all
NCT05712356 2026-05-26

BOLSTER

Lisata Therapeutics, Inc.

Phase 2 Terminated
66 enrolled 12 charts
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06282575 2026-05-11

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Jazz Pharmaceuticals

Phase 3 Recruiting
286 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07221253 2026-03-17

AB02

AstraZeneca

Phase 3 Recruiting
1,100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡